CVMP adopted positive opinion for a marketing authorisation for:
Bluevac-3, a new vaccine for the active immunisation of sheep to reduce the viraemia, mortality and clinical signs caused by the serotype 3 of the bluetongue virus, and for active immunisation of cattle to reduce the viraemia against the serotype 3 of the bluetongue virus.
for Syvazul BTV3, a new vaccine for the active immunisation of sheep to reduce viraemia, mortality, clinical signs and lesions caused by bluetongue virus serotype 3.
Nobilis Multriva REOm, a new vaccine for the active immunisation of chickens and to achieve passive immunisation of their progeny to reduce viraemia and clinical signs of disease caused by avian reovirus (ARV) genotypes 1 and 4.
and for variations requiring assessment concerning quality-related changes for Nobivac Bb and for Porcilis AR-T DF – Porcilis ColiClos – Porcilis Porcoli Diluvac Forte.